{"text": ["CORRECTING", "and", "REPLACING", "The", "Law", "Offices", "of", "Howard", "G.", "Smith", "Reminds", "Investors", "of", "Looming", "Deadline", "in", "the", "Class", "Action", "Lawsuit", "Against", "AbbVie", "Inc.", "(ABBV)"], "created_at": "2018-10-17 23:34:00"}
{"text": ["SHAREHOLDER", "ALERT:", "Pawar", "Law", "Group", "Announces", "a", "Securities", "Class", "Action", "Lawsuit", "Against", "AbbVie", "Inc.", "-", "ABBV"], "created_at": "2018-10-17 23:25:00"}
{"text": ["SHAREHOLDER", "ALERT:", "Pomerantz", "Law", "Firm", "Reminds", "Shareholders", "with", "Losses", "on", "their", "Investment", "in", "AbbVie", "Inc.", "of", "Class", "Action", "Lawsuit", "and", "Upcoming", "Deadline", "\u2013", "ABBV"], "created_at": "2018-10-17 20:00:00"}
{"text": ["Amgen", "Launches", "Humira", "Biosimilar", "in", "Europe"], "created_at": "2018-10-17 19:23:32"}
{"text": ["EyePoint", "(EYPT)", "Gets", "FDA", "Approval", "for", "Eye", "Therapy", "Yutiq"], "created_at": "2018-10-17 18:07:37"}
{"text": ["EyePoint", "(EYPT)", "Gets", "FDA", "Approval", "for", "Eye", "Therapy", "Yutiq"], "created_at": "2018-10-17 18:07:37"}
{"text": ["EyePoint", "(EYPT)", "Gets", "FDA", "Approval", "for", "Eye", "Therapy", "Yutiq"], "created_at": "2018-10-17 15:42:03"}
{"text": ["AbbVie", "Announces", "Supplemental", "New", "Drug", "Application", "Accepted", "for", "Priority", "Review", "by", "U.S.", "FDA", "for", "IMBRUVICA\u00ae", "(ibrutinib)", "in", "Combination", "with", "Obinutuzumab", "(GAZYVA\u00ae)", "for", "Previously", "Untreated", "Chronic", "Lymphocytic", "Leukemia", "(CLL)"], "created_at": "2018-10-17 12:00:00"}
{"text": ["Samsung", "launches", "third", "rival", "to", "AbbVie's", "Humira", "drug", "in", "EU"], "created_at": "2018-10-17 07:47:19"}
{"text": ["[$$]", "By", "Adding", "Patents,", "Drugmaker", "Keeps", "Cheaper", "Humira", "Copies", "Out", "of", "U.S."], "created_at": "2018-10-17 02:36:45"}
